Introduction & Agenda

  1. Letter to Participants from Dr. Christie Ballantyne
  2. LDL: Address the Risk Think Tank Agenda
  3. Interactive Table Discussion Questions

Clinical Trials & Practice Guidance

  1. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (NEJM – Cannon et al. 2015)
  2. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (NEJM – Sabatine et al. 2017)
  3. Novel Diabetes Drugs and the Cardiovascular Specialist (JACC – Sattar et al. 2017)
  4. Determining When to Add Nonstatin Therapy: A Quantitative Approach (JACC – Robinson et al. 2017)
  5. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients (NEJM – Ridker et al. 2017)
  6. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk (JACC -- Lloyd-Jones et al. 2017)

Risk Evaluation

  1. Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype (Circulation – Perak et al. 2016)
  2. Genetic Identification of Familial Hypercholesterolemia within a Single U.S. Health Care System. (Science – Abul-Husn et al. 2016)
  3. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. (JACC – Khera et al. 2016)
  4. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria (AJM – Virani et al. 2015)
  5. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention (JACC – Bohula et al. 2017)
  6. Prognostic Value of Coronary Artery Calcium Screening in Subjects With and Without Diabetes (JACC – Raggi et al. 2004)
  7. Cardiovascular Disease and Risk Management (Diabetes Care – 2017)
  8. Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology (JACC – Lloyd-Jones et al. 2017)

Registry Data

  1. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up (JACC – Perez et al. 2016)
  2. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry (Circulation – deGoma et al. 2016)
  3. Practice-Level Variation in Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry (JACC – Pokharel et al. 2016)

Systems of Care Data

  1. Predictors of Statin Use for Patients with LDL ≥190 mg/dL: Insights from the Veteran’s Affairs Health System (ACC.17 Poster)
  2. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs (Circulation – Virani et al. 2017)
  3. The Hidden Burden of EHR-Identified Familial Hypercholesterolemia: Mortality and Clinical Outcomes (Geisinger Poster)


  1. Falling Short of the Finish Line for the High-Risk Patient - S. Virani
  2. Session 1: Patient Cases - B. Duell
  3. Session 1: Distinguishing FH from non-FH - J. Knowles
  4. Session 1: When is ASCVD Risk Based on More than Just a Number - B. Duell
  5. Session 2: Patient Cases - K. Bircther
  6. Session 2: CV Risk Assessment in Patients with Diabetes - C. Ballantyne
  7. Session 2: When Statins Aren't Enough - K. Birtcher
  8. Session 3: Patient Cases - S. Virani
  9. Session 3: A Risky Game of Jeopardy Optimizing Statin Therapy is the Correct Answer - S. Virani
  10. Session 3: Utilizing Quantitative Data to Optimize Benefits of Non-Statin Therapies in Patients with ASCVD - J. Robinson
  11. Session 3: Coming to Consensus - C. Ballantyne